Update on Phase IIa Clinical

RNS Number : 6358U

Immupharma PLC

19 October 2010

 



For Immediate Release

19 October 2010

ImmuPharma plc

Update on Phase IIa Clinical Trial with Cancer Compound IPP-204106

ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company" or the "Group"), the specialist discovery and development pharmaceutical company is pleased to announce that at today's analyst briefing, Dr Robert Zimmer, Chief Scientific Officer, will give the following update on ImmuPharma's exciting Cancer programme IPP-204106, the summary of which is detailed below:

 Key Highlights:

·     Dose escalating open label study commenced in patients with at least one treatment failure according to standard regulatory guidelines;

·     The study was designed to show safety and tolerability and assess the maximum tolerated dose;

·     Patients are dosed with an initial dose of 40 mg/sq.m. or 1 mg/kg and if stabilisation or improvement occurs, then patients continue treatment for an additional 4 sessions;

·     6 patients have been dosed so far, suffering from either breast cancer, lung cancer and bladder cancer and all with metastasis;

·     No serious drug-related adverse events have so far been reported; and

·     2 patients have already been rated as having stabilised disease.

ImmuPharma plans to file a US IND in the next few months and to commence a Phase IIb programme the first half of 2011 in patients with metastatic melanoma, glioblastoma, hormone-resistant prostate cancer and pancreatic cancer, which will be confirmed by additional preclinical data.

For further information, please contact:

ImmuPharma PLC:

Dr Robert Zimmer, President & Chief Scientific Officer        + 33 389 32 76 50

Dimitri Dimitriou, Chief Executive Officer                               [phone]

Richard Warr, Chairman                                                        [phone]

Buchanan Communications

Lisa Baderoon, Mark Court, Jessica Fontaine                       [phone]

Panmure, Gordon & Co., NOMAD & Broker

Andrew Burnett, Rakesh Sharma                                           [phone]

Execution Noble & Co, Joint Broker

James Bromhead, Richard Crawley                                      [phone]

 

END

 

 

RESGGGQUUUPUGPB